Open AccessThe cost‐effectiveness of trastuzumab emtansine (T‐DM1) in HER2‐positive metastatic breast cancer is supported by clinical evidence
Author(s) -
Giuliani Jacopo,
Bonetti Andrea
Publication year - 2021
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/tbj.14024
Subject(s) - medicine , trastuzumab emtansine , trastuzumab , metastatic breast cancer , oncology , breast cancer , cancer